Published in Law and Health Weekly, June 10th, 2006
Furthermore, only 17% of the survey's respondents cite innovation as a key asset of Indian drug makers.
Bain's sampling of 179 international executives with headquarters in North America, Europe, Asia and India also expressed concerns about intellectual property protection (56%), parallel trade (52%) and regulatory uncertainty (46%) affecting the Indian industry.
"The Indian pharmaceutical industry now stands at the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly